---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-274908"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:16:44.871227+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion doses first T2D patient in Phase II of BMF-219; Phase I completed

## Summary
- First patient with type 2 diabetes dosed in Phase II portion of COVALENT-111 (Phase I/II) of BMF-219.
- Phase I healthy volunteer portion completed; BMF-219 well tolerated with favorable PK/PD profile.
- BMF-219 is the first menin inhibitor to reach clinic for type 2 diabetes; aims to restore beta cells.
- Initial Phase II data expected in first half of 2023; IND filing with FDA on track for Q4 2022.
- Preclinical data showed BMF-219 ability to restore beta cell mass in animal models of T2D.

## SEC filing metadata
- accession: 0001193125-22-274908
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/0001193125-22-274908-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312522274908/d350423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-274908
- JSON: https://secwatch.observer/filing/0001193125-22-274908.json
- Plain text: https://secwatch.observer/filing/0001193125-22-274908.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.